The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romieu, R.
Right arrow Articles by Viguier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romieu, R.
Right arrow Articles by Viguier, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Liver Cancer
The Journal of Immunology, 1998, 161: 5133-5137.
Copyright © 1998 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Passive But Not Active CD8+ T Cell-Based Immunotherapy Interferes with Liver Tumor Progression in a Transgenic Mouse Model1

Raphaëlle Romieu2,*, Myriam Baratin*, Michèle Kayibanda*, Valérie Lacabanne*, Marianne Ziol{dagger}, Jean-Gérard Guillet* and Mireille Viguier*

* Laboratoire des Pathologies Infectieuses et Tumorales, Institut National de la Santé et de la Recherche Médicale U445, Institut Cochin de Génétique Moléculaire, Université René Descartes, Paris, France; and {dagger} Service d’Anatomie Pathologique, Hôpital Jean Verdier, Bondy, France

To evaluate tumor immunotherapies, we used transgenic mice that harbor a progressive liver tumor associated with the expression of the SV40 large tumor T oncoprotein (SV40-T). To induce "self" tumor Ag-specific CD8+ T cells, mice were injected with an immunodominant SV40-T CTL epitope mixed with a heterologous helper peptide. Despite repeated injections, this vaccine failed to raise a tumor-specific CD8+ T cell response that was efficient enough to counteract tumors. Although coimmunization with SV40-T CTL epitope and heterologous helper peptide efficiently recruited the respective Th cells, only low-avidity SV40-T-specific CD8+ T cells were activated. Furthermore, major alterations in SV40-T-specific B and Th cell responses were characterized. In contrast, transfers of higher-avidity CTLs specific for the same SV40-T epitope were effective in counteracting tumors. These results suggest that passive therapies targeted to self tumor Ag may be more suitable than active immunization in the treatment of spontaneous tumors.




This article has been cited by other articles:


Home page
 BloodHome page
A. Roth, G. M. Baerlocher, M. Schertzer, E. Chavez, U. Duhrsen, and P. M. Lansdorp
Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT
Blood, July 1, 2005; 106(1): 43 - 50.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Belnoue, C. Guettier, M. Kayibanda, S. Le Rond, A.-M. Crain-Denoyelle, C. Marchiol, M. Ziol, D. Fradelizi, L. Renia, and M. Viguier
Regression of Established Liver Tumor Induced by Monoepitopic Peptide-Based Immunotherapy
J. Immunol., October 15, 2004; 173(8): 4882 - 4888.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Li, W. Li, S. Liang, D. Cai, M. P. Kieny, L. Jacob, A. Linnenbach, J. W. Abramczuk, H. Bender, K. Sproesser, et al.
Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice
J. Immunol., September 15, 2003; 171(6): 2922 - 2929.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Zheng, J.-X. Gao, H. Zhang, T. L. Geiger, Y. Liu, and P. Zheng
Clonal Deletion of Simian Virus 40 Large T Antigen-Specific T Cells in the Transgenic Adenocarcinoma of Mouse Prostate Mice: An Important Role for Clonal Deletion in Shaping the Repertoire of T Cells Specific for Antigens Overexpressed in Solid Tumors
J. Immunol., November 1, 2002; 169(9): 4761 - 4769.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Ganss, E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling
Combination of T-Cell Therapy and Trigger of Inflammation Induces Remodeling of the Vasculature and Tumor Eradication
Cancer Res., March 1, 2002; 62(5): 1462 - 1470.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Nishikawa, K. Tanida, H. Ikeda, M. Sakakura, Y. Miyahara, T. Aota, K. Mukai, M. Watanabe, K. Kuribayashi, L. J. Old, et al.
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity
PNAS, November 20, 2001; (2001) 251547298.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. D. Schell, B. B. Knowles, and S. S. Tevethia
Sequential Loss of Cytotoxic T Lymphocyte Responses to Simian Virus 40 Large T Antigen Epitopes in T Antigen Transgenic Mice Developing Osteosarcomas
Cancer Res., June 1, 2000; 60(11): 3002 - 3012.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. D. Schell, L. M. Mylin, I. Georgoff, A. K. Teresky, A. J. Levine, and S. S. Tevethia
Cytotoxic T-Lymphocyte Epitope Immunodominance in the Control of Choroid Plexus Tumors in Simian Virus 40 Large T Antigen Transgenic Mice
J. Virol., July 1, 1999; 73(7): 5981 - 5993.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Nishikawa, K. Tanida, H. Ikeda, M. Sakakura, Y. Miyahara, T. Aota, K. Mukai, M. Watanabe, K. Kuribayashi, L. J. Old, et al.
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity
PNAS, December 4, 2001; 98(25): 14571 - 14576.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.